CoQ10 Blood Test: What Your Levels Mean and Why They Decline With Age

What is Coenzyme Q10?

Coenzyme Q10 — also known as ubiquinone — is a fat-soluble compound found in virtually every cell in the human body. Its primary role is in the mitochondrial electron transport chain, where it is essential for the production of adenosine triphosphate (ATP), the molecule that powers cellular energy. Without adequate CoQ10, cells cannot generate the energy they need to function, and tissues with the highest energy demands — the heart, brain, kidneys, and liver — are the first to be affected.

Beyond energy production, CoQ10 functions as a potent lipid-soluble antioxidant, protecting cell membranes and circulating lipoproteins (particularly LDL cholesterol) from oxidative damage. This dual role — bioenergetic and antioxidant — makes it one of the most functionally important molecules in human physiology.

How is CoQ10 measured in the blood?

CoQ10 testing measures the total concentration of ubiquinone (the oxidised form) and ubiquinol (the reduced, active form) in the blood. At Masdiag, we quantify CoQ10 using LC-MS/MS from a dried blood spot — the same gold-standard analytical platform used across our biomarker panel. Normal reference ranges typically fall between 0.5 and 1.5 mg/L, though optimal levels for specific clinical contexts may differ.

An important consideration is that because CoQ10 is transported in the blood by lipoproteins, individuals with very high or very low cholesterol levels may show CoQ10 values that don't accurately reflect tissue status. Some clinicians therefore interpret CoQ10 relative to total cholesterol for a more precise assessment.

Why CoQ10 levels decline with age

The body synthesises CoQ10 endogenously, but production peaks around age 20 and declines progressively thereafter. By age 65, cardiac tissue CoQ10 concentrations may be 40–50% lower than at age 20. This age-related decline coincides with increased susceptibility to cardiovascular disease, neurodegenerative conditions, and reduced exercise capacity — all of which have been associated with CoQ10 depletion in clinical studies.

The statin connection

Statins — the most widely prescribed class of cholesterol-lowering drugs — inhibit HMG-CoA reductase, the same enzyme involved in the endogenous synthesis of CoQ10. Clinical evidence consistently shows that statin therapy reduces circulating CoQ10 levels by 20–40%, and this depletion has been proposed as a contributing factor to statin-associated muscle symptoms (SAMS), which affect an estimated 5–10% of statin users. Testing CoQ10 levels in statin users provides an objective basis for targeted supplementation.